Supplemental material
Systems Pharmacology Approach to Prevent Retinal Degeneration in
Stargardt Disease
Yu Chen, Grazyna Palczewska, Debarshi Mustafi, Marcin Golczak, Zhiqian Dong, Osamu
Sawada, Tadao Maeda, Akiko Maeda, and Krzysztof Palczewski
Table of Contents:
1. Supplemental Table 1.
2. Supplemental Table 2.
3. Supplemental Table 3.
4. References.
Supplemental Table 1. Expression of GPCRs in the eye and retina of C57BL/6J mice and the
retina of a human donor eye (normalized FPKM values)A. Human retina
AAnalyses were done as described in Materials and Methods. Transcriptome data were used to determine reads per kilobase of gene product per million reads (RPKM) for normalization and differential expression analyses. Higher expression values in the retina relative to the eye indicate their enrichment in retina. Such high values highlight those GPCRs that may be critical in the eye and retina for drug discovery and therapeutic approaches. Both processed and raw fastq files for transcriptome analyses were deposited in GEO (accession numbers GSE29752 Supplemental Table 2. Summary of pharmacologic agents targeting multiple GPCRs examined in the Abca4-/-
mouse bright light-induced retinopathy modelA.
Major action Efficacy Dose per
Brand name/
AVarious pharmacologic agents targeting multiple classes of GPCRs were examined for their effects on bright light-induced retinopathy in 4 to 5-week-old Abca4-/-Rdh8-/- mice. The name, major mechanism of action, efficacy (% of mice manifesting well-preserved retinal structure revealed by OCT imaging), dose and current clinical applications are indicated. Supplemental Table 3. Chemical structure of the pharmacologic agents coupling with multiple GPCRs
examined in the Abca4-/-Rdh8-/- mouse bright light-induced retinopathy model. GPCR coupling
Chemical structure
Guglielmo, R., Martinotti, G., Di Giannantonio, M., and Janiri, L. 2013. A possible new option for migraine management: agomelatine. Clin Neuropharmacol. 36:65-67. doi: de Bodinat, C., Guardiola-Lemaitre, B., Mocaer, E., Renard, P., Munoz, C., and Millan, M.J. 2010. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 9:628-642. doi: 610.1038/nrd3140. Epub 2010 Jun 1025. Hemrick-Luecke, S.K., Snoddy, H.D., and Fuller, R.W. 1994. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 55:479-483. Chanrion, B., Mannoury la Cour, C., Gavarini, S., Seimandi, M., Vincent, L., Pujol, J.F., Bockaert, J., Marin, P., and Millan, M.J. 2008. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol. 73:748-757. Cusack, B., Nelson, A., and Richelson, E. 1994. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 114:559- Schipper, J., Tulp, M.T., and Sijbesma, H. 1990. Neurochemical profile of eltoprazine. Drug Metabol Drug Interact. 8:85-114. Gommans, J., Hijzen, T.H., Maes, R.A., and Olivier, B. 1997. Discriminative stimulus properties of eltoprazine. Life Sci. 61:11-19. D'Amico, J.M., Murray, K.C., Li, Y., Chan, K.M., Finlay, M.G., Bennett, D.J., and Gorassini, M.A. 2013. Constitutively active 5-HT2/alpha1 receptors facilitate muscle spasms after human spinal cord injury. J Neurophysiol. 109:1473-1484. doi: 1410.1152/jn.00821.02012. Qiu, F., Qiu, C.Y., Liu, Y.Q., Wu, D., Li, J.D., and Hu, W.P. 2012. Potentiation of acid- sensing ion channel activity by the activation of 5-HT(2) receptors in rat dorsal root ganglion neurons. Neuropharmacology. 63:494-500. doi: 410.1016/j.neuropharm.2012.1004.1034. Epub Toll, L., Berzetei-Gurske, I.P., Polgar, W.E., Brandt, S.R., Adapa, I.D., Rodriguez, L., Schwartz, R.W., Haggart, D., O'Brien, A., White, A., et al. 1998. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 178:440-466. Glusa, E., and Pertz, H.H. 2000. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 130:692-698. Roscetti, G., Del Carmine, R., Trabucchi, M., Massotti, M., Purdy, R.H., and Barbaccia, M.L. 1998. Modulation of neurosteroid synthesis/accumulation by L-ascorbic acid in rat brain tissue: inhibition by selected serotonin antagonists. J Neurochem. 71:1108-1117. Prins, N.H., Briejer, M.R., and Schuurkes, J.A. 1997. Characterization of the contraction to 5-HT in the canine colon longitudinal muscle. Br J Pharmacol. 120:714-720. Eglen, R.M., Bley, K., Bonhaus, D.W., Clark, R.D., Hegde, S.S., Johnson, L.G., Leung, E., and Wong, E.H. 1993. RS 23597-190: a potent and selective 5-HT4 receptor antagonist. Br Schiavi, G.B., Brunet, S., Rizzi, C.A., and Ladinsky, H. 1994. Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Galeotti, N., Ghelardini, C., and Bartolini, A. 1998. Role of 5-HT4 receptors in the mouse passive avoidance test. J Pharmacol Exp Ther. 286:1115-1121. Hegde, S.S., Bonhaus, D.W., Johnson, L.G., Leung, E., Clark, R.D., and Eglen, R.M. 1995. RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist. Br J Medhurst, A.D., and Kaumann, A.J. 1993. Characterization of the 5-HT4 receptor mediating tachycardia in piglet isolated right atrium. Br J Pharmacol. 110:1023-1030. Sleight, A.J., Boess, F.G., Bos, M., Levet-Trafit, B., Riemer, C., and Bourson, A. 1998. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br J Pharmacol. 124:556-562. Bentley, J.C., Bourson, A., Boess, F.G., Fone, K.C., Marsden, C.A., Petit, N., and Sleight, A.J. 1999. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol. 126:1537-1542. Fone, K.C. 2008. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology. 1010.1016/j.neuropharm.2008.1006.1061. Epub 2008 Jul 1014. Wesolowska, A., and Nikiforuk, A. 2007. Effects of the brain-penetrant and selective 5- HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology. 52:1274-1283. Epub 2007 Jan 1220. Romero, G., Sanchez, E., Pujol, M., Perez, P., Codony, X., Holenz, J., Buschmann, H., and Pauwels, P.J. 2006. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol. 148:1133-1143. Epub Kim, H.J., Doddareddy, M.R., Choo, H., Cho, Y.S., No, K.T., Park, W.K., and Pae, A.N. 2008. New serotonin 5-HT(6) ligands from common feature pharmacophore hypotheses. J Chem Inf Model. 48:197-206. Epub 2007 Nov 2029. Hagan, J.J., Price, G.W., Jeffrey, P., Deeks, N.J., Stean, T., Piper, D., Smith, M.I., Upton, N., Medhurst, A.D., Middlemiss, D.N., et al. 2000. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol. 130:539-548. Lovell, P.J., Bromidge, S.M., Dabbs, S., Duckworth, D.M., Forbes, I.T., Jennings, A.J., King, F.D., Middlemiss, D.N., Rahman, S.K., Saunders, D.V., et al. 2000. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). J Med Chem. 43:342-345. Cushing, D.J., Zgombick, J.M., Nelson, D.L., and Cohen, M.L. 1996. LY215840, a high- affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J Pharmacol Exp Ther. 277:1560-1566. Lenglet, S., Louiset, E., Delarue, C., Vaudry, H., and Contesse, V. 2002. Activation of 5- HT(7) receptor in rat glomerulosa cells is associated with an increase in adenylyl cyclase activity and calcium influx through T-type calcium channels. Endocrinology. 143:1748-1760. Alabaster, V.A., and Davey, M.J. 1986. The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology. Br J Clin Pharmacol. 21:9S-17S. Mathe, J.M., Nomikos, G.G., Hildebrand, B.E., Hertel, P., and Svensson, T.H. 1996. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol. 309:1-11. Pickering, D.S., and Niles, L.P. 1990. Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur J Pharmacol. 175:71-77. Garcia-Sainz, J.A., Romero-Avila, M.T., Villalobos-Molina, R., and Minneman, K.P. 1995. Alpha 1-adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species. Eur J Pharmacol. 289:1-7. Taguchi, K., Saitoh, M., Sato, S., Asano, M., and Michel, M.C. 1997. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 280:1-5. Tsuchida, A., Liu, Y., Liu, G.S., Cohen, M.V., and Downey, J.M. 1994. alpha 1- adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res. 75:576-585. Heinonen, I., Wendelin-Saarenhovi, M., Kaskinoro, K., Knuuti, J., Scheinin, M., and Kalliokoski, K.K. 2013. Inhibition of alpha-adrenergic tone disturbs the distribution of blood flow in the exercising human limb. Am J Physiol Heart Circ Physiol 10:10. Evans, R.G., and Anderson, W.P. 1995. Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2- adrenoceptors. Br J Pharmacol. 116:1557-1570. Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. 1983. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in Intengan, H.D., and Smyth, D.D. 1997. Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance. J Pharmacol Exp Ther. 281:48-53. Gish, E.C., Miller, J.L., Honey, B.L., and Johnson, P.N. 2010. Lofexidine, an {alpha}2- receptor agonist for opioid detoxification. Ann Pharmacother. 310.1345/aph.1341M1347. Epub 2009 Dec 1329. Honey, B.L., Benefield, R.J., Miller, J.L., and Johnson, P.N. 2009. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother. 43:1506-1511. doi: 1510.1345/aph.1501M1161. Epub 2009 Aug Markham, A., and Wagstaff, A.J. 1998. Fexofenadine. Drugs. 55:269-274; discussion Gillard, M., and Chatelain, P. 2006. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol. 530:205-214. Epub 2006 Jan Nilvebrant, L., Andersson, K.E., Gillberg, P.G., Stahl, M., and Sparf, B. 1997. Tolterodine--a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 327:195-207. Cowart, M., Latshaw, S.P., Bhatia, P., Daanen, J.F., Rohde, J., Nelson, S.L., Patel, M., Kolasa, T., Nakane, M., Uchic, M.E., et al. 2004. Discovery of 2-(4-pyridin-2-ylpiperazin-1- ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem. 47:3853-3864. Glase, S.A., Akunne, H.C., Georgic, L.M., Heffner, T.G., MacKenzie, R.G., Manley, P.J., Pugsley, T.A., and Wise, L.D. 1997. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. J Med Chem. 40:1771-1772. Villamil-Hernandez, M.T., Alcantara-Vazquez, O., Sanchez-Lopez, A., and Centurion, D. 2013. Pharmacological identification of alpha- and alpha-adrenoceptor subtypes involved in the vasopressor responses induced by ergotamine in pithed rats. Eur J Pharmacol 22:00388-00389. Shi, W.X., and Bunney, B.S. 1992. Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons. J Neurosci. 12:2433- Flacco, N., Segura, V., Perez-Aso, M., Estrada, S., Seller, J.F., Jimenez-Altayo, F., Noguera, M.A., D'Ocon, P., Vila, E., and Ivorra, M.D. 2013. Different beta-adrenoceptor subtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels. Br J Pharmacol. 169:413-425. doi: 410.1111/bph.12121.



Head lice infestations: A clinical update Français en page 699 Head lice ( Pediculus humanus capitis ) infestations remain apesky communicable problem, particularly in school-agechildren in Canada and elsewhere (1,2). A small 2003population-based study (3) of primary school children in theUnited Kingdom noted a 2% prevalence and a 37% annualincidence of head lice. Unlike body lice, hea


AMVAC CHEMICAL CORPORATION Page 1 of 8 AMBUSH® 25W AMVAC MSDS No.: 297_3 MATERIAL SAFETY DATA SHEET CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME: AMBUSH® 25W Insecticide Wettable Powder; AMBUSH® 25W Insecticide Water Soluble Pack GENERAL USE: Insecticide PRODUCT DESCRIPTION: Off-white powder EPA Registration Number: 5481-502; 5481-503 MSDS No.: 297_3 MSD

Copyright © 2010-2014 Metabolize Drugs Pdf